ClinicalTrials.gg
CompletedNCT00095173Updated Jan 18, 2017Results posted

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

A Phase 3 interventional study of Abatacept and Placebo in Juvenile Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 36 sites in 11 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.

Enrollment
10th of 83
214 · median 55
Started
2003
the only one that year
Phase 3
30 of 109
5 open now
Registered
11th of 109
by date
Lead sponsor
5 of 109
Bristol-Myers Squibb

Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 10th largest by enrollment of the 83 interventional ones that give a count, is the only one that started in 2003, is one of 30 in phase 3, and was the 11th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Juvenile with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.

03

Conditions studied

  • Juvenile Rheumatoid Arthritis

Browse trials for

Keywords

  • Juvenile Idiopathic Arthritis
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis;
  • Current active arthritis;
  • Failed treatment with at least one disease modifying anti-rheumatic drug (DMARD);
  • Subjects must discontinue use of any DMARD other than methotrexate prior to the first dose of study medication

Exclusion criteria

Exclusion Criteria:

  • Presence of infection or history of frequent acute or chronic infections;
  • Joint replacement surgery required during the study or history of surgery on more than 5 joints;
  • within 3 months of the first dose of study medication;
  • Unresolved serious bacterial infection or chronic bacterial infection;
  • Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash, hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
214 participants (actual)

Study arms

  • Active comparator
    Abatacept

    Double Blind Period

    Drug: Abatacept

  • Placebo comparator
    Placebo

    Double Blind Period

    Drug: Placebo

  • Experimental
    Abatacept - Open Label

    Drug: Abatacept

Interventions

  • IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).

    Also known as: Orencia

  • DrugPlacebo

    IV infusions, IV, N/A, every 4 weeks, 6 months.

  • Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly

    Also known as: Orencia

06

What researchers measure

Primary outcomes

  1. Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)

    Time to flare is defined as the elapsed number of days between the first dose date in Period B and the study day that disease flare is confirmed. All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)

    Time frame: Period B (Day 113 to Day 282)

Secondary outcomes

  1. Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)

    All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)

    Time frame: Period B (Day 113 to Day 282)

  2. Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)

    AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

    Time frame: Period A (Day 1 to Day 113)

  3. Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Double-Blind Phase (Period B)

    AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

    Time frame: Period B (Day 113 to Day 282)

  4. Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Phase (Period C)

    AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 85 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

    Time frame: Period C (Day 282 to end of study)

  5. Median Percent Change From Baseline in JRA/JIA Core Set Variables During Double-Blind Phase (Period B)

    Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.

    Time frame: Period B (Day 113 to Day 282)

  6. Median Percent Change From Baseline in JRA/JIA Core Set Variables During Open-Label Phase (Period C)

    Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician's global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.

    Time frame: Period C (Day 282 to end of study)

  7. Events of Special Interest During Open-Label Lead-In Phase (Period A), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

    The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

    Time frame: Period A (Day 1 to Day 113)

  8. Events of Special Interest During Double-Blind Phase (Period B), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

    The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

    Time frame: Period B (Day 113 to Day 282)

  9. Events of Special Interest During Open-Label Phase (Period C), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

    The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

    Time frame: Period C (Day 282 up to 56 days after the last dose of study medication)

  10. Percentage of Participants Achieving American College of Rheumatology (ACR) Pediatric 30 (ACRP30), ACR Pediatric 50, ACR Pediatric 70, ACR Pediatric 90, and Inactive Disease Status Erythrocyte Sedimentation Rate (ESR) Response Rate

    The ACRP30 response criteria were defined as a ≥ 30% improvement over baseline in ESR. ACRP 50, 70, and 90 responses were defined similarly with 50%, 70%, and 90% improvements required, respectively.

    Time frame: Day 113, Day 282, and Day 2047

  11. Number of Treated Participants With Marked Laboratory Abnormalities During Open-Label Lead-In Phase (Period A)

    Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Alanine Aminotransferase, 0-40 units per liter (U/L);G-Glutamyl Transferase, 0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter (mg/dL);Blood Urea Nitrogen, 5.9-26.0 mg/dL;Creatinine, 0.50-1.50 mg/dL;Serum Potassium, 3.5-5.5 milliequivalents per liter (mEq/L);Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin, 3.5-5.5 g/dL;Urine Protein, \>=4;Urine Glucose, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.

    Time frame: Period A (Day 1 to Day 113)

  12. Number of Treated Participants With Marked Laboratory Abnormalities During Double-Blind Phase (Period B)

    Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Aspartate Aminotransferase, 0-40 units per liter (U/L); Alanine Aminotransferase, 0-40 U/L;Blood Urea Nitrogen, 5.9-26.0 mg/dL;Serum Sodium, 135-148 milliequivalents per liter (mEq/L);Serum Potassium, 3.5-5.5 mEq/L;Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Urine Protein, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.

    Time frame: Period B (Day 113 to Day 282)

  13. Number of Treated Participants With Marked Laboratory Abnormalities During Open-Label Phase (Period C)

    Marked abnormalities were pre-defined as changes in lab tests after drug infusion and relative to normal range. Hemoglobin,11.6-14.8grams per deciliter(g/dL);Hematocrit,36.0-50.0 percent;Erythrocytes,3.80-5.10x10\*6 cells per microliter(c/uL);Platelets,140-44 cells per liter(c/L);Leukocytes,4.00-12.50c/uL;Absolute(Abs)Neutrophils+Bands,\<1.00x10\^3 c/uL;Abs Lymphocytes,\<0.72x10\^3 or\>7.50x10\^3 c/uL;Abs Eosinophils,\>0.750X10\^3 c/uL;Alkaline Phosphatase,0-40 units per liter(U/L);Aspartate Aminotransferase,0-40 U/L;Alanine Aminotransferase,0-40U/L;G-Glutamyl Transferase,0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter(mg/dL);Blood Urea Nitrogen,5.9-26.0 mg/dL;Creatinine, 0.50-1.50mg/dL;Inorganic Phosphorus,2.8-6.2 U/L;Serum Potassium,3.5-5.5 milliequivalents per liter(mEq/L);Serum Glucose,65-99 mg/dL;Fasting Serum Glucose,65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin,3.5-5.5 g/dL;Urine Protein,\>=4;Urine Glucose,\>=4;Urine Blood,\>=4;Urine Red Blood Cells\>=4;Urine White Blood Cells,\>=4.

    Time frame: Period C (Day 282 to end of study)

  14. Number of Participants With Anti-Abatacept or Anti-CTLA4 Positive Responses Over Time During Open-Label Phase (Period C)

    During Period C, blood samples for immunogenicity assessments were obtained just prior to the start of the IV infusion of abatacept at 3-month intervals during the first 2 years of Period C, at 6-month intervals thereafter, and again 28, 56, and 85 days after the last infusion. Direct-format, enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the cytotoxic T-lymphocyte antigen 4 (CTLA4) and the anti-CTLA4-T antibody.

    Time frame: Period C (Day 282 to 85 days after the last dose of study medication)

07

Results

Posted Jan 18, 2017

Participant flow

Open-Label Lead-In Phase (Period A)
Participant flow — Open-Label Lead-In Phase (Period A)
MilestoneAbatacept (All Participants in Period A)Abatacept (Period B)Placebo (Period B)Abatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
Started19000000
Completed17000000
Not completed2000000
Withdrew: Adverse event100000
Withdrew: Lack of efficacy1700000
Withdrew: Withdrawal by subject100000
Withdrew: Other100000
Double-Blind Phase (Period B)
Participant flow — Double-Blind Phase (Period B)
MilestoneAbatacept (All Participants in Period A)Abatacept (Period B)Placebo (Period B)Abatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
Started06062000
Completed04931000
Not completed01131000
Withdrew: Lack of efficacy01031000
Withdrew: Withdrawal by subject010000
Open-Label Extension Phase (Period C)
Participant flow — Open-Label Extension Phase (Period C)
MilestoneAbatacept (All Participants in Period A)Abatacept (Period B)Placebo (Period B)Abatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
Started000365859
Completed000132927
Not completed000232932
Withdrew: Death000001
Withdrew: Adverse event000123
Withdrew: Lack of efficacy0001158
Withdrew: Lost to follow-up000256
Withdrew: Withdrawal by subject000460
Withdrew: No longer meets study criteria000011
Withdrew: Poor/non-compliance000022
Withdrew: Pregnancy000123
Withdrew: Other000468

Outcome measures

PrimaryTime to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)

Time to flare is defined as the elapsed number of days between the first dose date in Period B and the study day that disease flare is confirmed. All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)

Time frame:
Period B (Day 113 to Day 282)
Reported as:
Median · months
Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)
monthsAbatacept (Period B)Placebo (Period B)
Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)NA (NA to NA)6 (0.73 to 6.87)
Statistical analysis
  • Abatacept (Period B) vs Placebo (Period B) · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.31 · 95% CI 0.16 to 0.59Abatacept over placebo
SecondaryNumber of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)

All of the following criteria must be met to be defined as a flare: * \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables * \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables * ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare * worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)

Time frame:
Period B (Day 113 to Day 282)
Reported as:
Number · participants
Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)
participantsAbatacept (Period B)Placebo (Period B)
Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)1233
Statistical analysis
  • Abatacept (Period B) vs Placebo (Period B) · Chi-squared · p = <0.001
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

Time frame:
Period A (Day 1 to Day 113)
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)
participantsAbatacept (All Participants in Period A)
SAE6
Treatment-Related AE0
All Deaths0
Treatment-Related Deaths0
Discontinuation of Study Drug due to AEs1
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Double-Blind Phase (Period B)

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

Time frame:
Period B (Day 113 to Day 282)
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Double-Blind Phase (Period B)
participantsAbatacept (Period B)Placebo (Period B)
SAE02
Treatment-Related AE00
All Deaths00
Treatment-Related Deaths00
Discontinuation of Study Drug due to AEs00
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Phase (Period C)

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 85 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v14.1).

Time frame:
Period C (Day 282 to end of study)
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Phase (Period C)
participantsAbatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
SAE9912
Treatment-Related AE243
All Deaths001
Treatment-Related Deaths000
Discontinuation of Study Drug due to AEs123
SecondaryMedian Percent Change From Baseline in JRA/JIA Core Set Variables During Double-Blind Phase (Period B)

Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.

Time frame:
Period B (Day 113 to Day 282)
Reported as:
Median · percentage change from baseline
Median Percent Change From Baseline in JRA/JIA Core Set Variables During Double-Blind Phase (Period B)
percentage change from baselineAbatacept (Period B)Placebo (Period B)
Active Joints-20.9 (-92.0 to 17.86)50.00 (0.00 to 100.0)
Joints with LOM0.00 (-45.5 to 0.00)50.00 (0.00 to 100.0)
Physician Global Assessment-29.8 (-86.3 to 22.48)55.95 (-31.3 to 250.0)
Parent Global Assessment-11.2 (-56.8 to 28.41)8.39 (-31.8 to 100.0)
CHAQ Disability Index0.00 (-38.9 to 2.17)0.00 (-13.3 to 55.56)
ESR0.00 (-20.7 to 50.00)20.50 (-14.3 to 92.00)
CRP0.00 (-46.6 to 67.00)6.25 (-33.3 to 150.0)
SecondaryMedian Percent Change From Baseline in JRA/JIA Core Set Variables During Open-Label Phase (Period C)

Percent change from baseline was calculated from the difference between post-baseline and baseline divided by baseline multiplied by 100 and reported as the range between 25th and 75th percentile, not full range; American College of Rheumatology (ACR) Pediatric 30 JRA/JIA core set variables include active joints, limited range of motion, physician's global assessment of disease severity, parent global assessment of overall well-being, change in physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Disease activity was assessed by the physician and parent on a 0-100 mm visual analog scale (VAS). Low values represent low severity of disease and good well-being whereas high values represent highly severe disease and very poor well-being.

Time frame:
Period C (Day 282 to end of study)
Reported as:
Median · percentage change from baseline
Median Percent Change From Baseline in JRA/JIA Core Set Variables During Open-Label Phase (Period C)
percentage change from baselineAbatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
Active Joints-26.7 (-66.7 to 0.00)-70.2 (-94.1 to -50.0)-82.4 (-100 to -62.5)
Joints with Limited Range of Motion0.00 (-33.3 to 36.67)-50.0 (-75.0 to -27.3)-71.4 (-86.2 to -23.1)
Physician Global Assessment of Disease Severity-31.9 (-50.0 to -9.33)-75.0 (-91.3 to -52.3)-81.8 (-91.4 to -64.3)
Parent Global Assessment of Overall Well-Being1.96 (-19.6 to 26.67)-62.7 (-93.8 to -27.5)-63.9 (-84.2 to -38.8)
CHAQ Disability Index14.14 (-16.7 to 100.0)-56.7 (-81.8 to -18.2)-45.5 (-75.0 to -12.5)
ESR20.87 (-15.5 to 83.77)-27.3 (-54.8 to 20.00)-24.2 (-50.0 to 0.00)
CRP0.00 (-31.6 to 43.68)-33.8 (-84.4 to 54.84)-27.8 (-75.0 to 11.11)
SecondaryEvents of Special Interest During Open-Label Lead-In Phase (Period A), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

Time frame:
Period A (Day 1 to Day 113)
Reported as:
Number · participants
Events of Special Interest During Open-Label Lead-In Phase (Period A), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
participantsAbatacept (All Participants in Period A)
Infections and Infestations68
Peri-Infusional AEs30
Autoimmune Disorders2
Malignancies0
SecondaryEvents of Special Interest During Double-Blind Phase (Period B), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

Time frame:
Period B (Day 113 to Day 282)
Reported as:
Number · participants
Events of Special Interest During Double-Blind Phase (Period B), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
participantsAbatacept (Period B)Placebo (Period B)
Infections and Infestations2727
Peri-Infusional AEs22
Autoimmune Disorders00
Malignancies00
SecondaryEvents of Special Interest During Open-Label Phase (Period C), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies

The sponsor prospectively identified categories of AEs that may be associated with the use of immunomodulatory drugs including infections, peri-infusional AEs, autoimmune disorders, malignancies. Peri-infusional AEs are defined as those AEs of special interest occurring during the first 24 hours after the start of study drug infusion. Malignancies definitions were based on events in the MedDRA Maintenance and Support Services Organization (MSSO) malignancies Structured MedDRA Query (SMQ).Autoimmune disorders are in alignment with the pre-specified MedDRA codes of autoimmune disorders events of interest.

Time frame:
Period C (Day 282 up to 56 days after the last dose of study medication)
Reported as:
Number · participants
Events of Special Interest During Open-Label Phase (Period C), Including Infections, Peri-Infusional Adverse Events (AEs), Autoimmune Disorders and Malignancies
participantsAbatacept (All Participants in Period C)
Infections and Infestations120
Peri-Infusional AEs22
Autoimmune Disorders7
Malignancies1
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) Pediatric 30 (ACRP30), ACR Pediatric 50, ACR Pediatric 70, ACR Pediatric 90, and Inactive Disease Status Erythrocyte Sedimentation Rate (ESR) Response Rate

The ACRP30 response criteria were defined as a ≥ 30% improvement over baseline in ESR. ACRP 50, 70, and 90 responses were defined similarly with 50%, 70%, and 90% improvements required, respectively.

Time frame:
Day 113, Day 282, and Day 2047
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) Pediatric 30 (ACRP30), ACR Pediatric 50, ACR Pediatric 70, ACR Pediatric 90, and Inactive Disease Status Erythrocyte Sedimentation Rate (ESR) Response Rate
percentage of participantsAbatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
ACR Pediatric 30 (ESR) at Day 1130 (NA to NA)100 (NA to NA)100 (NA to NA)
ACR Pediatric 30 (ESR) at Day 282NA (NA to NA)84.5 (75.2 to 93.8)67.8 (55.9 to 79.7)
ACR Pediatric 30 (ESR) at Day 204769.2 (44.1 to 94.3)97.0 (91.1 to 100)86.7 (74.5 to 98.8)
ACR Pediatric 50 (ESR) at Day 1130 (NA to NA)65.5 (53.3 to 77.7)88.1 (79.9 to 96.4)
ACR Pediatric 50 (ESR) at Day 282NA (NA to NA)79.3 (68.9 to 89.7)52.5 (39.8 to 65.3)
ACR Pediatric 50 (ESR) at Day 204769.2 (44.1 to 94.3)93.9 (85.8 to 100.0)80.0 (65.7 to 94.3)
ACR Pediatric 70 (ESR) at Day 1130 (NA to NA)37.9 (25.4 to 50.4)49.2 (36.4 to 61.9)
ACR Pediatric 70 (ESR) at Day 282NA (NA to NA)55.2 (42.4 to 68.0)30.5 (18.8 to 42.3)
ACR Pediatric 70 (ESR) at Day 204753.8 (26.7 to 80.9)78.8 (64.8 to 92.7)63.3 (46.1 to 80.6)
ACR Pediatric 90 (ESR) at Day 1130 (NA to NA)17.2 (7.5 to 27.0)22.0 (11.5 to 32.6)
ACR Pediatric 90 (ESR) at Day 282NA (NA to NA)41.4 (28.7 to 54.1)15.3 (6.1 to 24.4)
ACR Pediatric 90 (ESR) at Day 204738.5 (12.0 to 64.9)66.7 (50.6 to 82.8)40.0 (22.5 to 57.5)
SecondaryNumber of Treated Participants With Marked Laboratory Abnormalities During Open-Label Lead-In Phase (Period A)

Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Alanine Aminotransferase, 0-40 units per liter (U/L);G-Glutamyl Transferase, 0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter (mg/dL);Blood Urea Nitrogen, 5.9-26.0 mg/dL;Creatinine, 0.50-1.50 mg/dL;Serum Potassium, 3.5-5.5 milliequivalents per liter (mEq/L);Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin, 3.5-5.5 g/dL;Urine Protein, \>=4;Urine Glucose, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.

Time frame:
Period A (Day 1 to Day 113)
Reported as:
Number · participants
Number of Treated Participants With Marked Laboratory Abnormalities During Open-Label Lead-In Phase (Period A)
participantsAbatacept (All Participants in Period A)
Hemoglobin (Low) n=1892
Hematocrit (Low) n=1892
Erythrocytes (Low) n=1891
Platelets (Low) n=1891
Platelet Count (High) n=1892
Leukocytes (Low) n=1899
Leukocytes (High) n=18910
Absolute Neutrophils + Bands (Low) n=1895
Absolute Lymphocytes (Low) n=1899
Absolute Eosinophils (High) n=18916
Alanine Aminotransferase (ALT, High) n=1902
G-Glutamyl Transferase (GGT, High) n=1901
Bilirubin (Total, High) n=1901
Blood Urea Nitrogen (High) n=1906
Creatinine (High) n=19012
Potassium (High) n=1904
Serum Glucose (Low) n=19026
Serum Glucose (High) n=1902
Fasting Serum Glucose (High) n=1091
Total Protein (High) n=1902
Albumin (Low) n=1902
Urine Protein (High) n=19012
Urine Glucose (High) n=1901
Urine Blood (High) n=19023
Urine White Blood Cells (High) n=759
Urine Red Blood Cells (High) n=7525
SecondaryNumber of Treated Participants With Marked Laboratory Abnormalities During Double-Blind Phase (Period B)

Marked abnormalities were pre-defined as changes in lab tests that occurred after drug infusion and were reported relative to the normal range for each analyte. Hemoglobin, 11.6-14.8 grams per deciliter (g/dL);Hematocrit, 36.0-50.0 percent;Erythrocytes, 3.80-5.10x10\*6 cells per microliter (c/uL);Platelets, 140-44 cells per liter (c/L);Leukocytes, 4.00-12.50 c/uL;Absolute Neutrophils + Bands, if \<1.00x10\^3 c/uL;Absolute Lymphocytes, if \<0.72x10\^3 or \>7.50x10\^3 c/uL;Absolute Eosinophils, if \>0.750X10\^3 c/uL;Aspartate Aminotransferase, 0-40 units per liter (U/L); Alanine Aminotransferase, 0-40 U/L;Blood Urea Nitrogen, 5.9-26.0 mg/dL;Serum Sodium, 135-148 milliequivalents per liter (mEq/L);Serum Potassium, 3.5-5.5 mEq/L;Serum Glucose, 65-99 mg/dL;Fasting Serum Glucose, 65-99 mg/dL;Urine Protein, \>=4;Urine Blood, \>=4;Urine Red Blood Cells \>=4;Urine White Blood Cells, \>=4.

Time frame:
Period B (Day 113 to Day 282)
Reported as:
Number · participants
Number of Treated Participants With Marked Laboratory Abnormalities During Double-Blind Phase (Period B)
participantsAbatacept (Period B)Placebo (Period B)
Hemoglobin (Low) n=60, 6111
Hematocrit (Low) n=60, 6111
Erythrocytes (Low) n=60, 6101
Platelets (Low) n-60, 6140
Platelets (High) n=18901
Leukocytes (Low) n=60, 6111
Leukocytes (High) n=60, 6112
Absolute Neutrophils + Bands (Low) n=60, 6201
Absolute Lymphocytes (Low) n=60, 6223
Absolute Eosinophils (High) n=60, 6264
Aspartate Aminotransferase (AST, High) n=60, 6210
Alanine Aminotransferase (ALT, High) n=60, 6210
Blood Urea Nitrogen (High) n=60, 6211
Serum Sodium (Low) n=60, 6201
Serum Potassium (High) n=60, 6220
Serum Glucose (Low) n=60, 6245
Serum Glucose (High) n=60, 6201
Fasting Serum Glucose (High) n=60, 6211
Urine Protein (High) n=6222
Urine Blood (High) n=60, 62126
Urine White Blood Cells (High) n=24, 2052
Urine Red Blood Cells (High) n=24, 2064
SecondaryNumber of Treated Participants With Marked Laboratory Abnormalities During Open-Label Phase (Period C)

Marked abnormalities were pre-defined as changes in lab tests after drug infusion and relative to normal range. Hemoglobin,11.6-14.8grams per deciliter(g/dL);Hematocrit,36.0-50.0 percent;Erythrocytes,3.80-5.10x10\*6 cells per microliter(c/uL);Platelets,140-44 cells per liter(c/L);Leukocytes,4.00-12.50c/uL;Absolute(Abs)Neutrophils+Bands,\<1.00x10\^3 c/uL;Abs Lymphocytes,\<0.72x10\^3 or\>7.50x10\^3 c/uL;Abs Eosinophils,\>0.750X10\^3 c/uL;Alkaline Phosphatase,0-40 units per liter(U/L);Aspartate Aminotransferase,0-40 U/L;Alanine Aminotransferase,0-40U/L;G-Glutamyl Transferase,0-60 U/L;Bilirubin, 0.1-1.2 milligrams per deciliter(mg/dL);Blood Urea Nitrogen,5.9-26.0 mg/dL;Creatinine, 0.50-1.50mg/dL;Inorganic Phosphorus,2.8-6.2 U/L;Serum Potassium,3.5-5.5 milliequivalents per liter(mEq/L);Serum Glucose,65-99 mg/dL;Fasting Serum Glucose,65-99 mg/dL;Total Protein, 6.0-8.5 g/dL;Albumin,3.5-5.5 g/dL;Urine Protein,\>=4;Urine Glucose,\>=4;Urine Blood,\>=4;Urine Red Blood Cells\>=4;Urine White Blood Cells,\>=4.

Time frame:
Period C (Day 282 to end of study)
Reported as:
Number · participants
Number of Treated Participants With Marked Laboratory Abnormalities During Open-Label Phase (Period C)
participantsAbatacept (All Participants in Period C)
Hemoglobin (Low) n=15312
Hematocrit (Low) n=1538
Erythrocytes (Low) n=1534
Platelet Count (Low) n=1534
Platelet Count (High) n=1535
Leukocytes (Low) n=15320
Leukocytes (High) n=15318
Absolute Neutrophils + Bands (Low)14
Absolute Lymphocytes (Low) n=15321
Absolute Lymphocytes (High) n=1535
Absolute Eosinophils (High) n=15350
Alkaline Phosphatase (ALP, High) n=1532
Aspartate Aminotransferase (AST, High)5
Alanine Aminotransferase (ALT, High) n=15311
G-Glutamyl Transferase (GGT, High) n=1536
Bilirubin (Total, High) n=1533
Blood Urea Nitrogen (High) n=15315
Creatinine (High) n=15336
Potassium (High) n=15310
Inorganic Phosphorus (High) n=1534
Serum Glucose (Low) n=15354
Serum Glucose (High) n=1531
Fasting Serum Glucose (Low) n=10011
Fasting Serum Glucose (High) n=1007
Total Protein (Low) n=1531
Total Protein (High) n=1531
Albumin (Low) n=1539
Urine Protein (High) n=15335
Urine Glucose (High) n=1531
Urine Blood (High) n=15373
Urine White Blood Cells (High) n=11749
Urine Red Blood Cells (High) n=11786
SecondaryNumber of Participants With Anti-Abatacept or Anti-CTLA4 Positive Responses Over Time During Open-Label Phase (Period C)

During Period C, blood samples for immunogenicity assessments were obtained just prior to the start of the IV infusion of abatacept at 3-month intervals during the first 2 years of Period C, at 6-month intervals thereafter, and again 28, 56, and 85 days after the last infusion. Direct-format, enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the cytotoxic T-lymphocyte antigen 4 (CTLA4) and the anti-CTLA4-T antibody.

Time frame:
Period C (Day 282 to 85 days after the last dose of study medication)
Reported as:
Number · participants
Number of Participants With Anti-Abatacept or Anti-CTLA4 Positive Responses Over Time During Open-Label Phase (Period C)
participantsAbatacept (Period A Non-Responders in Period C)Abatacept (Period C)Placebo (Period B) to Abatacept (Period C)
Anti-Abatacept, Overall on Treatment (n=31,54,54)152
Anti-Abatacept, Post-Treatment (n=25,41,38)033
Anti-CTLA4-T, Overall on Treatment (n=33,57,58)444
Anti-CTLA4-T, Overall Post-Treatment (n=27,46,42)411

Adverse events

Collected over From first dose to last dose plus 56 days up to end of study (November 2011). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept (Only Period A)—4/32 (12.5%)22/32 (68.8%)
Abatacept (Period A/Period C)—10/36 (27.8%)32/36 (88.9%)
Abatacept (Period A/Period B)—9/60 (15%)57/60 (95%)
Abatacept (Period A)/Placebo (Period B)—14/62 (22.6%)54/62 (87.1%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventAbatacept (Only Period A)Abatacept (Period A/Period C)Abatacept (Period A/Period B)Abatacept (Period A)/Placebo (Period B)
ArthritisMusculoskeletal and connective tissue disorders0/323/363/600/62
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/321/360/601/62
AppendicitisInfections and infestations0/320/362/600/62
Ovarian cystReproductive system and breast disorders1/320/360/600/62
Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/320/360/600/62
Abscess limbInfections and infestations0/321/360/600/62
Condition aggravatedGeneral disorders0/321/360/600/62
Herpes zosterInfections and infestations0/321/360/600/62
Meningitis bacterialInfections and infestations0/321/360/600/62
TorticollisMusculoskeletal and connective tissue disorders0/321/360/600/62
Most frequent other events
Showing 10 of 80
Most frequent other events
EventAbatacept (Only Period A)Abatacept (Period A/Period C)Abatacept (Period A/Period B)Abatacept (Period A)/Placebo (Period B)
Upper respiratory tract infectionInfections and infestations3/3212/3611/6012/62
NasopharyngitisInfections and infestations3/3211/3620/6015/62
HeadacheNervous system disorders7/3210/3614/6011/62
InfluenzaInfections and infestations1/326/3616/6012/62
DiarrhoeaGastrointestinal disorders2/328/3611/6015/62
PyrexiaGeneral disorders2/328/3612/6012/62
CoughRespiratory, thoracic and mediastinal disorders4/327/3610/6013/62
PharyngitisInfections and infestations0/323/3610/6013/62
VomitingGastrointestinal disorders2/327/369/6013/62
SinusitisInfections and infestations1/325/3612/607/62

Baseline characteristics

All treated participants in the Lead-In Phase (Period A)

Age, Continuous
Age, Continuous(years)Abatacept (All Participants in Period A)
Median13.0 (5.0 to 17.0)
Gender
Gender(Participants)Abatacept (All Participants in Period A)
Female137
Male53
08

Study locations

36 sites
  • Omaha, Nebraska, United States
  • Livingston, New Jersey, United States
  • New Hyde Park, New York, United States
  • Valhalla, New York, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Duncansville, Pennsylvania, United States
  • Dallas, Texas, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Local Institution
    Bregenz, Austria
  • Local Institution
    Botucatu, Brazil
  • Local Institution
    Rio de Janeiro, Brazil
  • Local Institution
    Sao Paulo, Brazil
  • Local Institution
    Paris, France
  • Local Institution
    Strasbourg, France
  • Local Institution
    Berlin, Germany
  • Local Institution
    Bremen, Germany
  • Local Institution
    Halle, Germany
  • Local Institution
    Hamburg, Germany
  • Local Institution
    Firenze, Italy
  • Local Institution
    Genova, Italy
  • Local Institution
    Milano, Italy
  • Local Institution
    Napoli, Italy
  • Local Institution
    Roma, Italy
  • Local Institution
    Trieste, Italy
  • Local Institution
    Guadalajara, Mexico
  • Local Institution
    Mexico City, Mexico
  • Local Institution
    Monterrey, Mexico
  • Local Institution
    Puebla, Mexico
  • Local Institution
    San Luis Potosi, Mexico
  • Local Institution
    Lima, Peru
  • Local Institution
    Lisboa, Portugal
  • Local Institution
    La Coruna, Spain
  • Local Institution
    Valencia, Spain
  • Local Institution
    Lausanne, Switzerland
09

References and documents

Publications

  • Ruperto N, Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Cimaz R, Dare J, Espada G, Faugier E, Ferrandiz M, Gerloni V, Quartier P, Silva CA, Wagner-Weiner L, Gandhi Y, Passarell J, Nys M, Wong R, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. J Rheumatol. 2021 Jul;48(7):1073-1081. doi: 10.3899/jrheum.200154. Epub 2021 Jan 15. PubMed 33452173 ↗
  • Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Job Deslandre C, Minden K, Punaro M, Block AJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015 Oct;67(10):2759-70. doi: 10.1002/art.39234. PubMed 26097215 ↗
  • Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Alcala JO, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace C, Alessio M, Quartier P, Cortis E, Eberhard A, Simonini G, Lemelle I, Chalom EC, Sigal LH, Block A, Covucci A, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1542-51. doi: 10.1002/acr.20283. Epub 2010 Jul 1. PubMed 20597110 ↗
  • Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010 Jun;62(6):1792-802. doi: 10.1002/art.27431. PubMed 20191582 ↗
  • Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008 Aug 2;372(9636):383-91. doi: 10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14. PubMed 18632147 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Jun 2006 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 10 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2004
First posted
Nov 2, 2004
Start
Dec 2003
Primary completionActual
Jun 2006
CompletionActual
Nov 2011
Results first posted
Jan 18, 2017
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00095173
Responsible party
Sponsor
First posted
Nov 2, 2004
Start date
Dec 2003
Primary completion
Jun 2006
Completion
Nov 2011
Results posted
Jan 18, 2017
Last update
Jan 18, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion